Bank Of America Corp Tempest Therapeutics, Inc. Transaction History

Bank Of America Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2025 May 15, 2025	BUY	$0.77 - $9.59 $13 - $172	18 Added 5.44%	349 $3,000
Q4 2024 Feb 14, 2025	SELL	$0.7 - $1.45 $30,011 - $62,165	-42,873 Reduced 99.23%	331 $0
Q3 2024 Nov 14, 2024	SELL	$0.96 - $2.23 $50 - $118	-53 Reduced 0.12%	43,204 $60,000
Q2 2024 Aug 14, 2024	BUY	$2.01 - $5.44 $458 - $1,240	228 Added 0.53%	43,257 $94,000
Q1 2024 May 15, 2024	BUY	$3.16 - $4.66 $17,591 - $25,942	5,567 Added 14.86%	43,029 $168,000
Q4 2023 Feb 14, 2024	BUY	$0.23 - $9.77 $8,614 - $365,915	37,453 Added 416144.44%	37,462 $164,000
Q1 2023 May 12, 2023	SELL	$1.14 - $2.91 $6 - $17	-6 Reduced 40.0%	9 $0
Q4 2022 Feb 10, 2023	BUY	$1.15 - $2.12 $6 - $12	6 Added 66.67%	15 $0
Q3 2022 Nov 14, 2022	SELL	$1.62 - $2.76 $3,240 - $5,520	-2,000 Reduced 99.55%	9 $0
Q2 2022 Aug 12, 2022	BUY	$2.08 - $4.15 $2,281 - $4,552	1,097 Added 120.29%	2,009 $4,000
Q3 2021 Nov 15, 2021	BUY	$10.49 - $24.19 $818 - $1,886	78 Added 9.35%	912 $13,000
Q2 2021 Sep 13, 2021	BUY	$11.18 - $22.95 $9,324 - $19,140	834 New	834 $9,000

820K

400

Ticker TPST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,418,900
Market Cap $105M
Description
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.